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MODERN TREATMENT METHODS OF THE LOCALIZED 
INFLAMMATORY RESPONSE IN ACUTE CEREBRAL 
ISCHEMIA. 
 
The article shows the results of a complex study of the leading index 
changes of the cytokine profile in patients with the brain infarction (BI) in 
the course of therapy with human cryopreserved cord blood serum (CCBS). 
Plasma levels of proinflammatory cytokines (interleukine-6 (IL-6), tumor 
necrosis factor-α (TNF-α)) as well as anti-inflammatory factors – IL-4, 
IL-10 were tested in the blood serum of 350 patients in the mentioned medi-
cal condition on the 1
st
, 10
th
 and 21
st
 days of therapy. 
All patients were divided into 2 groups: the 1
st
 one (n = 175) got undif-
ferentiated therapy with the additional administration of acetylsalicylic acid 
(ASA); the 2
nd
 one (n = 175) got the therapy of 1
st
 group complemented by 
administration of 1 ml of CCBS within 10 days. Additionally there were 2 
more clinical sub-groups distinguished by National Institutes of Health 
Stroke Scale (NIHSS) according to disease severity level: A group (n = 183) 
included patients in medium severity condition; B group (n = 167) com-
prised patients in critical condition. Plasma levels of IL-4, IL-6, IL-10 and 
TNF-α were specified by means of enzyme-linked immunosorbent analysis. 
Summing up the above-mentioned, it is certain that the imbalance in 
immune system functioning, represented by a simultaneous lytic level in-
crease of both proinflammatory (IL-6, TNF-α) and anti-inflammatory (IL-4, 
IL-10) cytokines, is observed shortly after the start of BI. 
Additional administration of CCBS in a therapeutic complex caused 
more considerable and more rapid stabilization of proinflammatory factor 
values, which were ultimately close to the control ones. This substantially 
influenced the course of disease and its prognosis. The research showed no 
accurate reduction in anti-inflammatory cytokines levels of ІL-4 and ІL-10 
which indicated intensive localized inflammatory response even at the end 
of the acute period of disease. However, comparing the mentioned values 
with those of the patients who were not additionally treated with CCBS, 
lower value levels have to be acknowledged. It may be explained by a more 
efficient and incipient reduction of proinflammatory cytokines concentration 
in the course of disease, which in its turn results in normalization of ІL-4 and 
ІL-10 levels. 
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СУЧАСНІ МОЖЛИВОСТІ ЛІКУВАННЯ ЛОКАЛЬНОЇ 
ЗАПАЛЬНОЇ РЕАКЦІЇ ПІД ЧАС ГОСТРОЇ ЦЕРЕБРАЛЬНОЇ 
ІШЕМІЇ.  
  
В статті наведені результати комплексного вивчення 
особливостей змін провідних показників цитокінового профілю 
хворих на інфаркт головного мозку (ІГМ) в динаміці лікування 
кріоконсервованою сироваткою кордової крові (КСКК) людини. 
Були досліджені плазмові рівні як прозапальних цитокінів 
(інтерлейкін-6 (ІЛ-6), фактор некрозу пухлин-α (ФНП-α)), так і 
протизапальних чинників – ІЛ-4, ІЛ-10 в сироватці крові 350 хворих 
з даною патологією на 1-шу, 10-ту і 21-шу добу лікування. 
Всі хворі були розділені на 2 групи: 1-ша (n = 175), що 
отримувала недиференційовану терапію з додатковим 
призначенням ацетилсаліцилової кислоти (АСК); 2-га (n = 175) – 
терапія 1-ої групи, що була доповнена введенням 1 мл КСКК 
протягом 10 діб. За допомогою National Institutes of Health Stroke 
Scale (NIHSS) також було виділено 2 клінічні підгрупи за ступенем 
тяжкості: А (n = 183) – хворі в стані середнього ступеня тяжкості; В 
(n = 167) – хворі в тяжкому стані. Визначення плазмових рівнів ІЛ-
4, ІЛ-6, ІЛ-10, ФНП-α проводили методом твердофазного 
імуноферментного аналізу. 
В результаті було отримано дані про те, що вже з перших годин 
ІГМ спостерігається дисбаланс у функціонуванні імунної системи, 
який проявляється в одночасному літичному підвищенні рівнів як 
прозапальних (ІЛ-6, ФНП-α), так і протизапальних (ІЛ-4, ІЛ-10) 
цитокінів. 
Додаткове застосування у лікувальному комплексі КСКК 
викликало більш значну та швидку стабілізацію значень 
прозапальних чинників, які були максимально наближені до 
контрольних, що суттєво впливало на перебіг і прогноз 
захворювання. Достовірного зниження рівнів протизапальних 
цитокінів ІЛ-4 та ІЛ-10 у ході дослідження виявити не вдалося, що 
говорить про вираженість локальної запальної реакції навіть на 
кінець гострого періоду захворювання. Але порівнюючи значення 
їх із групою хворих, що додатково не отримували КСКК, 
доводиться констатувати все ж таки більш низькі рівні даних 
показників. Можливо це пояснюється більш чітким і раннім 
зниженням концентрацій прозапальних цитокінів у динаміці 
захворювання, що в свою чергу призводить до нормалізації рівнів 
ІЛ-4 і ІЛ-10. 
Ключові слова: імунологічний моніторинг, цитокін, запалення, 
ішемія, інтерлейкін, дисбаланс.  
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Introduction 
The localized inflammatory response of the 
brain tissue within acute anoxia occurs due to 
rapid formation of cytokines, which are specific 
bioregulatory glycoproteins. By their functional 
properties they are divided into pro- and anti-
inflammatory units [1, 2]. 
Interleukine-6 (ІL) is one of the main triggers 
of the cytokine system in acute brain infarction 
(BI), which acts as a potent promotor of the 
hypothalamo-pituitary-adrenal axis via the 
transmembrane receptors gp130 [3], and is 
synthesized not only by the cells of the immune 
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system (monocytes, macrophages, lymphocytes, 
microglial cells), but also by endotheliocytes, 
astrocytes and unstriated myocytes of blood vessels 
[4, 5]. 
Except being a mediator of inflammatory 
processes, tumor necrosis factor-α (TNF-α) is also a 
key molecule in regulation of normal differentiation, 
development and metabolism of different tissues [6, 
7]. Due to its binding to the targeting membrane 
receptors at molecular level the signaling events are 
started that result in activating the transcription 
factors which in their turn control the activity of 
genes which encode the fusion of proinflammatory 
cytokines and cause a programmed cell death [8, 9]. 
TNF-α promotes the universal transcription factor 
NF-kB, a group of multifunctional intracellular 
signaling pathways involving mitogen-activated 
protein kinases which control gene expression of 
immune response, apoptosis, proliferation, cell cycle 
control and angiogenesis [10, 11]. 
In the course of BI the presence of cerebral 
endothelium is frequently distinguished. That is 
TNF-α which makes special importance in its 
progression. TNF-α is proved to promote 
endothelium permeability, increase 
procoagulantive capacity and reduce 
anticoagulative features along with accumulation 
of immune cells in tissues. TNF-α can also start 
the signaling events which result in activating the 
endotheliocytes apoptosis in vitro [6, 12]. 
In the course of acute cerebral ischemia an 
extensive induction of TNF-α is caused by the 
oxidative stress and glutamate exitotoxity after the 
very first hour of neurologic disorder onset [13]. 
In the human’s body there also exists an 
antagonist of the proinflammatory cytokine system 
which deactivates acute stress reactions. These 
effects can be realized due to the hyperproduction of 
anti-inflammatory triggers [14], one of which is IL-4. 
It is involved in Т-helpers differentiation, controls 
the production of TNF-α, IL-1β, IL-6 and IL-8, 
activates the macrophages, and strengthens their 
cytotoxic capabilities. In the course of acute hypoxia 
of brain tissue the maximum value of ІL-4 gene 
expression is reached in first 6 hours, while the factor 
synthesis peaks in 48 hours. The highest production 
of ІL-4 in vitro is observed on the 3rd day [15]. 
The mentioned cytokine promotes expression of 
the products of class II major histocompatibility 
system as well as antigen-presenting cells. To some 
extent it can be regarded as a functional analogue of 
interferon-γ [16, 17]. ІL-4 causes an anti-
inflammatory effect by deactivating the functions of 
macrophages and their secretion of ІL-1, ІL-6, ІL-8 
and TNF-α [18]. 
Another important anti-inflammatory cytokine is 
ІL-10, which is primarily produced by such immune 
cells as Т-helpers, В-lymphocytes, monocytes and 
macrophages. An acute cerebral hypoxia causes the 
hyperproduction of ІL-10 by these cells [19]. 
It acts as an inflammation inhibitor due to 
synthesis depression of other cytokines, chemokines 
and adhesive molecules, primarily of TNF-α, ІL-1, 
ІL-6, ІL-12 and others. This cytokine can depress the 
effector functions of macrophages, Т-killers, 
neutrophils, synthesis of interferon-γ, the process of 
expression of adhesion molecules and alternatively 
stimulate chemotaxis, poliferation and thymocytes 
maturation [20, 21]. 
Being a protective factor for vascular 
endothelium, ІL-10 greatly decreases the action of 
angiotonin II in the course of BI, which is always 
activated by the outputs of oxidative stress. It can 
modulate the reconstruction of vessels, reduce 
adhesion of leucocytes, improve leucocytal and 
endothelial interaction and provide vasodilatation by 
increased production of NO [22, 23]. 
Various immunoinflammatory reflexes are 
observed almost in all kinds of acute cerebrovascular 
pathology, while BI is the classic case of amicrobic 
inflammatory process which starts along with 
forming the necrotic zone of brain tissue and directly 
influences the damage severity. The intensity of 
system reactions in the course of inflammation is 
mainly determined by the levels of proinflammatory 
cytokines, prostaglandins, kinin and some hormones 
with leading values of ІL-6 and TNF-α [24]. The 
initial rapid increase of their content in blood is the 
appropriate response of the immune system to the 
caused damage and has to promote the recruitment of 
immunodefence. Therefore, the immune monitoring 
in BI follow-up is prior in this case. It makes 
possible to estimate the level of damage and to make 
prognosis of the further course and outcome of 
disease [1, 25]. 
The objective was to perform a complex study of 
the character of changes of cytokine profile based on 
the patients’ medical condition in acute brain 
infarction in the course of therapy with CCBS in 
order to estimate its immune modulating properties. 
Methods and materials. The levels of 
proinflammatory (ІL-6 and TNF-α) and anti-
inflammatory (ІL-4 and ІL-10) cytokines were 
studied in the blood serum of 350 patients in 
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mentioned medical condition during their 
hospitalization on the 1
st
, 10
th
 and 21
st
 days of 
therapy in order to determine the degree of changes 
of cytokine profile in the course of BI. 
The patients with BI were treated with a solution 
of human cryopreserved cord blood serum (CCBS) 
“Cryocell-cryocord”, which contained a set of 
different hemopoietins, growth factors, adaptogens 
and reproductive immune response-modulating 
agents. The solution was developed and produced by 
SI of ISC of Cryobiology and Cryomedicine of the 
National Academy of Sciences of Ukraine, Academy 
of Medical Sciences and Ministry of Health Care of 
Ukraine (Kharkiv, Ukraine). 
According to the medicamentous therapy all 
patients were randomly divided into 2 groups before 
the start of treatment: the 1
st
 one (n = 175) got 
undifferentiated treatment with the additional 
administration of ASA; the 2
nd
 one (n = 175) got 
undifferentiated therapy with the additional 
administration of ASA complemented by 
administration of 1 ml of CCBS solution 
intravenously within 10 days. Both groups of 
patients had the same clinical features of disease, 
comorbidity, age and sex. 
The patients were graded by National Institutes 
of Health Stroke Scale (NIHSS) according to their 
disease condition and the degree of neurologic deficit 
by 15 indexes, which were stated in points rated at 
the first hours of disease and in the course of therapy 
on the 10
th
 and 21
st
 day. Thus, all patients were 
divided into 2 clinical sub-groups: A group (n = 183) 
included patients in medium severity condition (an 
avarage point scaled by NIHSS in the 1
st
 group was 
11.74 ± 0.33 and 11.61 ± 0.22 in the 2nd one); B 
group (n = 167) comprised patients in critical 
condition (an avarage point scaled by NIHSS in the 
1
st
 group was 23.11 ± 0.37 and 24.06 ± 0.29 in the 
2
nd
 one). 
Plasma levels of IL-4, IL-6, IL-10 and TNF-α 
were specified by enzyme-linked immunosorbent 
analysis. The statistical results were processed by 
Statistica 6.0 program. 
Results. The analysis showed that average values 
of ІL-6 proved to be the highest in blood serum of 
the patients with BI at the moment of hospitalization. 
At the same time these values exceeded the indexes 
of the control group almost ten-fold (34.33 ± 
2.9 pg/ml in patients with severe BI compared to 
3.51 ± 0.28 pg/ml in the control group, р < 0.001). 
Patients with medium severity condition of BI had 5 
times higher ІL-6 indexes (17.62 ± 2.3 pg/ml, р < 
0.001) than the control group. The detected changes 
can indicate a considerable and early stress of the 
cytokine system in all patients, which is maximal in 
severe BI. 
All severity-specific sub-groups of both groups 
had a firm reduction of plasma levels of ІL-6 after 
the therapy compared to the indexes at the moment 
of hospitalization (р < 0.05). In A sub-groups of both 
groups the levels of ІL-6 were close to each other on 
the 10
th
 day of disease. There was a certain reduction 
of indexes compared to those of the 1
st
 day after the 
acute neurological symptoms onset by 15.5 % and 
37.3 %, respectively. It is attributable to the fact that 
in the not-critical brain tissue injury the levels of 
proinflammatory cytokines can approach to the 
stated values within a shorter period of time than in 
severe conditions. Apparently it takes place due to 
the early activation of anti-inflammatory factors. 
On the 10
th
 day reliably lower values of ІL-6 
were detected in patients with severe BI of the 2
nd
 
group in comparing to the corresponding indexes of 
the patients not treated with CCBS (р < 0.05) 
additionally. As for the percentage correlation the 
levels of ІL-6 in patients with severe BI of the 2nd 
group reliably reduced by 48.5% on the 10
th
 day of 
disease whereas the 1
st
 group showed the reduction 
only by 30.1 %. Still a considerable difference in 
18.4% can be indicative of the anti-inflammatory 
effects of CCBS being presented even in 
considerable injuries. 
On the 21
st
 day of therapy the levels of ІL-6 were 
close to the control values almost in all groups of 
patients. It was clearly observed in patients of the 2
nd
 
group of A sub-group additionally treated with 
CCBS. 
Seriously ill patients of both groups showed the 
highest TNF-α values (20.15 ± 0.71 and 21.06 ± 
0.50 pg/ml correspondingly). This fact indicated the 
maximal strain of the cytokin system in the course of 
severe BI. Patients in severe condition of all sub-
groups and patients in medium severity condition in 
the 1
st
 group had tendency to reduction of TNF-
α values on the 10th day of BI comparing to initial 
indexes registered on the 1
st
 day, but it was not 
statistically significant. While analyzing the indexes 
of the 2
nd
 group, the reduction of TNF-α levels was 
also noticed in patients of both severity-specific sub-
groups on the 10
th
 day of disease, which was 
statistically significant only in the severe condition 
group of patients (р < 0.05). 
A certain reduction of TNF-α level was also 
observed in patients of the 2
nd
 sub-group on the 21
st
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day of therapy, but its average value (7.24 ± 
0.22 pg/ml) was a bit higher than that of A sub-group 
(5.34 ± 0.15 pg/ml). The patients of the 2nd group 
with severe BI additionally treated with CCBS had a 
considerably lower level of TNF-α than the patients 
of the 1
st
 group (р < 0.05): 7.24 ± 0.22 pg/ml and 
12.63 ± 0.47 pg/ml, correspondingly. 
The study showed that patients with severe BI 
had the highest level of anti-inflammatory cytokin 
ІL-4 in blood serum at the moment of 
hospitalization. Besides, its level was almost 3,6 
times higher than the indexes in the control group 
(5.28 ± 0.34 pg/ml in both sub-groups compared to 
1.48 ± 0.21 pg/of ml of the control group, р < 0.001). 
Patients in medium severity condition of BI also had 
higher ІL-4 indexes than those of the control group, 
but only by 2.5 times (3.74 ± 0.69 pg/ml, р < 0.05). 
The detected changes can be indicative of a 
functional strain of the anti-inflammatory system in 
all patients with BI which is fully observed in the 
course of severe conditions. 
On the 10
th
 day of therapy lower values of ІL-4 
were detected in patients with severe BI of the 2
nd
 
group in comparing to the corresponding indexes of 
the 1
st
 group (р < 0.05). As for the percentage 
correlation, the levels of ІL-4 in patients with severe 
BI of the 2
nd
 group reliably reduced by 28.3% on the 
10
th
 day of disease whereas the 1
st
 group showed the 
reduction only by 17.9 %.  
On the 21
st
 day of the therapy the changes in 
levels of the mentioned index proved to be positive, 
since the values were close to the control ones almost 
in all groups of patients. It was firmly stated in 
patients of the 2
nd
 group of A sub-group additionally 
treated with CCBS. Patients with severe BI had the 
highest level values of ІL-4 (3.25 ± 0.29 pg/ml) on 
the 21
st
 day of a standard medical therapy, which still 
exceeded the control indexes by 2.2 times. 
Besides, the patients with acute BI had the 
highest level of ІL-10 in blood plasma on the 1st day 
of the therapy, while it exceeded the indexes of the 
control group almost by 4,4 times (2.52 ± 0.44 pg/ml 
in both sub-groups compared to 0.57 ± 0,17 pg/ml of 
the control group, р < 0.001). Patients in medium 
severity condition of BI had 3.5 times higher ІL-10 
indexes (2.00 ± 0.16 pg/ml, р < 0.05) than the 
patients in the control group. 
In the course of the therapy all severity-specific 
sub-groups of both groups had reduction of ІL-6 
levels in blood plasma compared to the indexes of 
the first day. On the 10
th
 day of the therapy, the 
patients in medium severity condition of BI had a 
slight reduction of index values compared to those 
stated at the moment of hospitalization, still it was 
not statistically significant. Similar findings proved 
to be in both groups of patients with severe condition 
(р > 0.05). 
On the 21
st
 day of the therapy the changes in 
levels of IL-10 in blood serum gradually reduced 
almost in all groups of patients, but the values didn’t 
even get close to those of the control group. A 
certain reduction of ІL-10 levels was stated only 
when comparing the values studied at the moment of 
hospitalization and on the 21
st
 day of disease in both 
sub-groups of the group of patients which were 
additionally treated with CCBS in 3,6 and 2 times, 
correspondingly. 
The direct correlation relationship between an 
average clinical result scaled by NIHSS and values 
of ІL-6 (r = + 0.89; p < 0.05), TNF-α (r = + 0.89; p < 
0.05) ІL-4 (r = + 0.95; p < 0.05) and ІL-10 (r = 
+ 0.97; p < 0.05) was fixed in the course of statistical 
analysis. This correlation persisted throughout the 
therapy and was indicative of dependence of 
cytokine levels in blood plasma and a patient state in 
disease onset.  
The direct correlation relationship between the 
levels of ІL-6 and ІL-4 (r = +0,87; p < 0,05), TNF-α 
and ІL-4 (r = +0.86; p < 0.05), ІL-6 and ІL-10 (r = 
+ 0.91; p < 0.05) as well as TNF-α and ІL-10 (r = 
+ 0.88; p < 0.05) is indicative of the potent 
simultaneous activation of pro- and anti-
inflammatory cytokin systems in the course of BI. 
Discussion. The measured changes of the cytokin 
system enable us to regard them as a special incipient 
and adaptable body mechanism in acute BI. The 
disease severity level is one of the key factors, which 
can substantially influence the degree of changes of 
leading pro- and anti-inflammatory factors. The 
results of the experiment suggest that CCBS has a 
powerful immunomodulating effect due to involving 
the interferons and anti-inflammatory cytokins (ІL-4, 
ІL-8 and ІL-10). 
 
Conclusions  
Summing up the above-mentioned, it is certain 
that the imbalance in immune system functioning, 
represented by a simultaneous lytic level increase 
of both proinflammatory (IL-6, TNF-α) and anti-
inflammatory (IL -4, IL -10) cytokines, is observed 
shortly after the start of BI. 
The detected characteristics confirm the direct 
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relation of the indicated factors to the early onset of 
both activation and suppression of the localized 
starting reaction because of the ischemic injury of 
brain tissue and their further functioning in the 
pathogenetic mechanisms of the acute cerebral 
ischemia progression. 
Additional administration of CCBS in a 
therapeutic complex caused more considerable and 
more rapid stabilization of IL-6 and TNF-α values, 
which were ultimately close to the control ones. 
This substantially influenced the course of disease 
and its prognosis. The research showed no accurate 
reduction in anti-inflammatory cytokines levels of 
ІL-4 and ІL-10, which indicated intensive localized 
inflammatory response even at the end of the acute 
period of disease. However, comparing the 
mentioned values with those of the patients who 
were not additionally treated with CCBS, lower 
value levels have to be acknowledged. It may be 
explained by a more efficient and incipient 
reduction of proinflammatory cytokines 
concentration in the course of disease, which in its 
turn results in normalization of ІL-4 and ІL-10 
levels. 
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